Compositions and methods related to anti-EGFR antibody drug conjugates
In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (\"EGFR\") antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
Kim; Yong Zu (Daejeon, KR), Park; Yun Hee (Daejeon, KR), Choi; Hyo Jung (Daejeon, KR), Jung; Ji Eun (Daejeon, KR), Ryu; Jeong Hee (Daejeon, KR), Song; Ho Young (Daejeon, KR), Chae; Jeiwook (Daejeon, KR), Chung; Chul-Woong (Daejeon, KR)
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.